Author

J. Bergwik

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

A. Egesten· 2 shared L. Tanner· 2 shared C. Dong· 1 shared C. Kalderen· 1 shared I. Boldogh· 1 shared L. Pan· 1 shared M. Adner· 1 shared R. K. Bhongir· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. Egesten

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

OGG1 inhibitor TH5487 alleviates allergic airway inflammation in mice

L. Tanner, J. Bergwik, R. K. Bhongir, L. Pan, C. Dong, C. Kalderen, T. Helleday, I. Boldogh, M. Adner, A. Egesten

This study shows that TH5487, an OGG1 inhibitor, reduces allergic airway inflammation in mice by decreasing mucus production, immune cell recruitment, and proinflammatory cytokines.

bioRxiv · May 17, 2022 · PreprintPharmacology & Toxicology

Zoledronic acid targets the mevalonate pathway causing reduced cell recruitment and attenuation of pulmonary fibrosis

L. Tanner, J. Bergwik, R. K. V. Bhongir, A. Egesten

This study shows zoledronic acid reduces pulmonary fibrosis by targeting the mevalonate pathway, decreasing myofibroblast transition and immune cell recruitment in a mouse model.

bioRxiv · Dec 1, 2021 · PreprintPharmacology & Toxicology